Trial Profile
Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 07 Dec 2021 Planned End Date changed from 31 Dec 2023 to 31 Dec 2021.
- 17 May 2021 Planned primary completion date changed from 31 Mar 2021 to 31 Dec 2021.